Structured Abstract
Introduction Adenomyosis is an under-recognised condition in which definitive diagnosis is only possible via histology after hysterectomy, an unacceptable option for those wishing to preserve fertility. Recent cellular/molecular studies indicate adenomyotic lesions may be fibrotic leading to increased uterine tissue stiffness. 3D Magnetic Resonance Elastography (MRE) is a novel imaging technique that allows in vivo measurement of tissue stiffness (via elastograms). 3D MRE has not been reported to study adenomyosis. The feasibility study aimed to utilise a novel 3D MRE protocol to measure global uterine stiffness and to investigate its potential application for non-invasive in vivo diagnosis of adenomyosis.
Materials and Methods 3D MRE protocol was conducted on one healthy volunteer (control) and four patients with suspected adenomyosis and heavy menstrual bleeding (HMB), diagnosed via transvaginal ultrasound and clinical history (REC:20/SS/0123 and 19/SS/0102). Two patients underwent hysterectomy, and representative uterine tissue samples were assessed for (i) histological presence of adenomyosis via H&E staining; (ii) cellular/molecular measures of tissue stiffness (collagen [picrosirius red], α-smooth muscle actin, e-cadherin); (iii) relationship between in vivo assessment of the uterus via MRI images and 3D MRE findings with in vitro uterine tissue histology from the same individuals.
Results 3D MRE was successfully used to acquire elastograms for four patients with adenomyosis (diffuse n=3, focal n=1) and one healthy volunteer. Calculated global uterine stiffness was higher in women with adenomyosis (2.93kPa; range 2.34 – 3.39kPa) compared to a healthy volunteer (2.04kPa). Areas of stiffness on 3D elastograms reflected adenomyotic changes visualised via conventional MRI, with the added benefit of also correlating with histology/immunohistochemical assessment for markers of tissue stiffness.
Discussion A novel 3D MRE protocol has been applied to obtain the global uterine stiffness in four women with HMB and suspected adenomyosis, and one healthy volunteer. 3D MRE has the potential to provide superior non-invasive tissue characterisation in vivo when compared to conventional MRI in the assessment of adenomyosis due to the correlation of imaging and tissue findings. Further studies are now needed to confirm the above exploratory findings, prior to performing a potential clinical trial.
Competing Interest Statement
HODC has received clinical research support for laboratory consumables and staff from Bayer AG (paid to institution) and provides consultancy advice (paid to institution) to Bayer AG, PregLem SA, Gedeon Richter, Vifor Pharma UK Ltd, AbbVie Inc., and Myovant Sciences GmbH. HODC has received royalties from UpToDate for an article on abnormal uterine bleeding. VJ received salary and research consumables support from Wellbeing of Women (WoW).
NR reports a relationship with Rohto Pharmaceutical Company that includes: consulting or advisory and funding grants (Project BONNIE). Mayo Clinic owns Resoundant, Inc. JC owns stock in and intellectual property rights with Resoundant, Inc.
The Mayo Clinic and RLE have intellectual property rights and a financial interest related to magnetic resonance elastography.
Funding Statement
The study was funded by University of Edinburgh's Institute for Regeneration & Repair (IRR) Early Career Researcher's Innovation Award 2022, MRC Centre for Reproductive Health (MRC Centre grants: G1002033 and MR/N022556/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
South East Scotland Research Ethics Committee 002 and NHS Lothian Research and Development gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
